Register for free to listen to this article
Listen with Speechify
0:00
1:00

ROCKVILLE, Md. – OriGene Technologies Inc. announced theacquisition of Marligen Biosciences Inc., a provider of cutting-edge multiplexassays for the Luminex xMAP platform for protein and gene expression profiling assays and testingservices, and DNA and RNA purification kits. 

 

The acquisition reinforces OriGene's leading position in thebio-medical research industry by expanding the scope of its gene centric toolboxportfolio and further represents another step in OriGene's aggressive growthplan.

 

The acquisition will enhance OriGene's gene centric productportfolio to include new assay panels and custom assays for drugdiscovery.  Leveraging OriGene'shigh throughput monoclonal antibody production capability, OriGene intends tocomplete its development of high quality assay panels and custom assays forresearchers that will dramatically hasten and increase efficiencies for drugdiscovery. OriGene's mammalian cell expressed proteins maintain the mostauthentic protein structure, post-translational modifications and functions. 

 

WithMarligen's assay development expertise and a strong menu of kits and reagents,and the complementary assets and strengths of OriGene's product line, OriGenewill provide a complete product solution to fully address the needs of drugdiscovery researchers. By acquiring Marligen, OriGene has increased itscritical mass and enhanced its competitive strength for creating a gene centricproduct line which researchers can use to accelerate drug discovery andcellular analysis.  All ofMarligen's key talent will be retained by OriGene at its new state-of-art researchfacility in Rockville, Md. 

Related Topics

Published In

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue